Increased risk of disseminated cryptococcal infection in a patient with multiple sclerosis on fingolimod
Autor: | Abdul Basit, Zaman Muhammad, Alana Lewis, Pushpinder Kaur, Nikolas St. Cyr |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty 030106 microbiology Case Report Infectious and parasitic diseases RC109-216 medicine.disease_cause Multiple sclerosis 03 medical and health sciences 0302 clinical medicine medicine 030212 general & internal medicine Autoimmune disease business.industry Varicella zoster virus Meningoencephalitis Fingolimod medicine.disease Dermatology Infectious Diseases Increased risk Disseminated cryptococcal Coinfection business Oral retinoid medicine.drug |
Zdroj: | IDCases, Vol 22, Iss, Pp e00961-(2020) IDCases |
ISSN: | 2214-2509 |
Popis: | Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system (CNS), with an estimated 2.3 million people being affected globally, and is a major cause of permanent disability. About 90 % of the affected patients with MS have relapsing-remitting type. Fingolimod became the first FDA approved oral drug in 2010 with an immunomodulating mechanism to control the relapse rates. However, since its introduction, increased cases of cryptococcal infections have been reported including meningoencephalitis and disseminated infections. Herein, we present the case of a 34-year-old-male with disseminated Cryptococcal and localized varicella zoster virus (VZV) coinfection to highlight the risk of opportunistic infections associated with the long-term use of fingolimod. The objective of this literature review is for clinicians to have a high index of suspicion for cryptococcal infections when dealing with MS patients on Fingolimod, especially those who present with neurological symptoms, as this mimics MS relapse. |
Databáze: | OpenAIRE |
Externí odkaz: |